{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:24:21Z","timestamp":1789208661667,"version":"build-2803163510"},"reference-count":27,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2012,12,15]],"date-time":"2012-12-15T00:00:00Z","timestamp":1355529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2012,12,15]],"date-time":"2012-12-15T00:00:00Z","timestamp":1355529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; No studies to date have assessed the efficacy\/tolerability of degarelix in the relief of lower urinary tract symptoms (LUTS) secondary to prostate cancer (PrCa). &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Patients were randomised to degarelix 240\/80 mg or goserelin 3.6 mg + bicalutamide flare protection (G+B); both treatments were administered for 3 months. The primary endpoint was change in International Prostate Symptom Score (IPSS) at week 12 compared with baseline. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; This study was stopped early due to recruitment difficulties. 40 patients received treatment (degarelix n = 27; G+B n = 13); most had locally advanced disease and were highly symptomatic. Degarelix was non-inferior to G+B in reducing IPSS at week 12 in the full analysis set (p = 0.20); the significantly larger IPSS reduction in the per-protocol analysis (p = 0.04) was suggestive of superior reductions with degarelix. Significantly more degarelix patients had improved quality of life (IPSS question) at week 12 (85 vs. 46%; p = 0.01). Mean prostate size reductions at week 12 were 42 versus 25% for patients receiving degarelix versus G+B, respectively (p = 0.04; post hoc analysis). Most adverse events were mild\/moderate; more degarelix patients experienced injection site reactions whereas more G+B patients had urinary tract infections\/cystitis. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; In 40 men with predominantly locally advanced PrCa and highly symptomatic LUTS, degarelix was at least non-inferior to G+B in reducing IPSS at week 12.<\/jats:p>","DOI":"10.1159\/000345423","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T09:19:44Z","timestamp":1355735984000},"page":"321-328","source":"Crossref","is-referenced-by-count":44,"title":["Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)"],"prefix":"10.1159","volume":"90","author":[{"given":"John","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghandi","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Benejam","family":"Gual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gomez Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Colli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Eric","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2012,12,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1017\/S0959259809990463"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.02.018"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2010.02.006"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.09.054"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04658.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000113964.68020.a7"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01391.x"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-006-0075-1"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31819cd364"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000225412.24750.4c"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0017"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.12.070"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08183.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.11.029"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.07.033"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.04.065"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2009.03.024"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.01.061"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.112326"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1360"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.8.3721"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21289"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-1439(00)00124-1"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990180402"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61831-7"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00273-4"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001283"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/345423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/345423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:35:38Z","timestamp":1745433338000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000345423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,15]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,4,1]]},"published-print":{"date-parts":[[2013,4,18]]}},"URL":"https:\/\/doi.org\/10.1159\/000345423","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"value":"0042-1138","type":"print"},{"value":"1423-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,15]]}}}